Skip to main content
Top
Published in: Surgery Today 10/2012

01-10-2012 | Case Report

Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case

Authors: Takafumi Watanabe, Takaki Yoshikawa, Yoichi Kameda, Toru Aoyama, Tsutomu Hayashi, Takashi Ogata, Haruhiko Cho, Akira Tsuburaya, Satoshi Morita, Yumi Miyashita, Junichi Sakamoto

Published in: Surgery Today | Issue 10/2012

Login to get access

Abstract

We report a case of advanced gastric carcinoma treated successfully by four courses of neoadjuvant chemotherapy (NAC) with paclitaxel and cisplatin. The patient was a 43-year-old man with advanced gastric cancer, clinically diagnosed as P0H0M0CY0T3N2, which had invaded the upper body of the stomach and esophagus. He was entered into a clinical trial and received the following NAC regimen: paclitaxel 80 mg/m2, and cisplatin 25 mg/m2, on days 1, 8, and 15, followed by a rest on day 22, as one course. The lymph nodes had reduced in size to 59% after two courses and to 40% after four courses, with no sign of severe toxicity. Subsequently, he underwent D2 total gastrectomy with pancreatico-splenectomy. On microscopic examinations, no tumor cells were detected in the ulcer scar of the resected stomach or the regional lymph nodes. Thus, we discuss the potential of long-term NAC, especially for responders to two initial courses.
Literature
1.
go back to reference Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol. 2003;21:274–5.CrossRef Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol. 2003;21:274–5.CrossRef
2.
go back to reference Díaz de Liaño A, Yarnoz C, Aguilar R, Artieda C, Ortiz H. Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer. 2008;11:96–102. Díaz de Liaño A, Yarnoz C, Aguilar R, Artieda C, Ortiz H. Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer. 2008;11:96–102.
3.
go back to reference Ott K, Lordick F, Hermann K, Krause B-J, Schuhmacher C, Siewert JR. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. 2008;11:1–9.CrossRefPubMed Ott K, Lordick F, Hermann K, Krause B-J, Schuhmacher C, Siewert JR. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. 2008;11:1–9.CrossRefPubMed
4.
go back to reference Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed
5.
go back to reference Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40(4):295–300.CrossRefPubMed Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40(4):295–300.CrossRefPubMed
6.
go back to reference Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96(9):1015–22.CrossRefPubMed Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96(9):1015–22.CrossRefPubMed
7.
go back to reference Yoshikawa T, Omura K, Kobayashi O, Nishimoto A, Takabayashi A, Yamada T, et al. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol. 2010;36:546–51.CrossRefPubMed Yoshikawa T, Omura K, Kobayashi O, Nishimoto A, Takabayashi A, Yamada T, et al. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol. 2010;36:546–51.CrossRefPubMed
8.
go back to reference Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S, et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer. 2003;6:45–9.CrossRefPubMed Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S, et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer. 2003;6:45–9.CrossRefPubMed
9.
go back to reference Satoh S, Hasegawa S, Ozaki N, Okabe H, Watanabe G, Nagayama S, et al. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer. 2006;9:129–35.CrossRefPubMed Satoh S, Hasegawa S, Ozaki N, Okabe H, Watanabe G, Nagayama S, et al. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer. 2006;9:129–35.CrossRefPubMed
10.
go back to reference Sakurai K, Yamashita Y, Shimizu S, Yoshida K, FDukuoka T, Xiang Z, et al. A case of advanced gastric cancer responding to S-1 chemotherapy for three weeks. Jpn J Cancer Chemother. 2010;37:315–8. Sakurai K, Yamashita Y, Shimizu S, Yoshida K, FDukuoka T, Xiang Z, et al. A case of advanced gastric cancer responding to S-1 chemotherapy for three weeks. Jpn J Cancer Chemother. 2010;37:315–8.
11.
go back to reference Mori S, Kishimoto H, Tauchi K, Higuchi K. Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy. Gastric Cancer. 2006;9:136–9.CrossRefPubMed Mori S, Kishimoto H, Tauchi K, Higuchi K. Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy. Gastric Cancer. 2006;9:136–9.CrossRefPubMed
12.
go back to reference Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer. 1998;1:10–24.CrossRefPubMed Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer. 1998;1:10–24.CrossRefPubMed
13.
go back to reference Nagata N, Kimura M, Hirabayashi N, Tsuburaya A, Murata T, Kondo K, et al. Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer. Hepatogastroenterology. 2008;55:1846–50.PubMed Nagata N, Kimura M, Hirabayashi N, Tsuburaya A, Murata T, Kondo K, et al. Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer. Hepatogastroenterology. 2008;55:1846–50.PubMed
14.
go back to reference Yoshikawa T, Tsuburaya A, Morita S, Kodera Y, Ito S, Cho H, et al. A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS). Jpn J Clin Oncol. 2010;40:369–72.CrossRefPubMed Yoshikawa T, Tsuburaya A, Morita S, Kodera Y, Ito S, Cho H, et al. A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS). Jpn J Clin Oncol. 2010;40:369–72.CrossRefPubMed
15.
go back to reference Kinoshita T, Sasako M, Sano T, Katai H, Furukawa H, Tsuburaya A, et al. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG0002). Gastric Cancer. 2009;12:37–42.CrossRefPubMed Kinoshita T, Sasako M, Sano T, Katai H, Furukawa H, Tsuburaya A, et al. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG0002). Gastric Cancer. 2009;12:37–42.CrossRefPubMed
16.
go back to reference Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.CrossRefPubMed Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.CrossRefPubMed
17.
go back to reference Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer. 2009;12:69–78.CrossRefPubMed Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer. 2009;12:69–78.CrossRefPubMed
18.
go back to reference Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89:2207–12.CrossRefPubMedPubMedCentral Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89:2207–12.CrossRefPubMedPubMedCentral
19.
go back to reference Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–9.CrossRefPubMed Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–9.CrossRefPubMed
Metadata
Title
Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case
Authors
Takafumi Watanabe
Takaki Yoshikawa
Yoichi Kameda
Toru Aoyama
Tsutomu Hayashi
Takashi Ogata
Haruhiko Cho
Akira Tsuburaya
Satoshi Morita
Yumi Miyashita
Junichi Sakamoto
Publication date
01-10-2012
Publisher
Springer Japan
Published in
Surgery Today / Issue 10/2012
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-012-0155-3

Other articles of this Issue 10/2012

Surgery Today 10/2012 Go to the issue